Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Feno Monaco

Pain Medicine Pittsburgh, PA Medical Doctor

NPI 1104267830 CMS profile 736581

320 East North Tower, S Tower, 2Nd Floor, Pittsburgh, PA 15212

Open in the dashboard

General payments

$11,765

167 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Feno Monaco of Pittsburgh, PA is reported in the CMS Open Payments database as having received $11,765 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,756 17
2024 General $1,033 13
2023 General $1,829 22
2022 General $1,365 19
2021 General $1,941 26
2020 General $1,553 21
2019 General $2,287 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Feno Monaco
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Feno Monaco were reported at $1,756. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Feno Monaco Pain Medicine median Middle half National median
2019 $2,287 $498 $126–$1,682 $163
2020 $1,553 $284 $80–$910 $114
2021 $1,941 $399 $112–$1,219 $132
2022 $1,365 $455 $137–$1,484 $149
2023 $1,829 $484 $128–$1,495 $160
2024 $1,033 $498 $131–$1,540 $164
2025 $1,756 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $9,200 105 payments
  2. Medtronic USA, Inc. $525 11 payments
  3. Medtronic, Inc. $523 5 payments
  4. SI-BONE, Inc. $499 12 payments
  5. TerSera Therapeutics LLC $149 8 payments
  6. Stryker Corporation $134 1 payment
  7. Relievant Medsystems, Inc. $131 1 payment
  8. Siemens Medical Solutions USA, Inc. $122 2 payments
  9. MML US, Inc. $118 1 payment
  10. Scilex Pharmaceuticals Inc. $113 6 payments
  11. Other $253 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,765 167 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $2,607 27 payments
  2. PROCLAIM Neuromodulation $1,325 14 payments
  3. Proclaim IPG $832 9 payments
  4. PROCLAIM Neuromodulation $613 5 payments
  5. ETERNA Neuromodulation $572 6 payments
  6. ETERNA Structural Heart $535 4 payments
  7. PENTA $515 5 payments
  8. PROCLAIM Structural Heart $503 4 payments
  9. INTELLIS $412 10 payments
  10. PROCLAIM Structural Heart $411 5 payments
  11. Other $3,334 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

747

Median for Pain Management: 951

Drug cost

$17,030

Median for Pain Management: $26,034

Branded share of claims

28.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 25 $5,606
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 158 $3,261
Gabapentin Generic 163 $2,978
Oxycodone Hcl Generic 80 $1,230
Tramadol Hcl Generic 113 $1,037
Pregabalin Generic 35 $865
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 46 $842
Duloxetine Hcl Generic 11 $360
Tizanidine Hcl Generic 49 $291
Morphine Sulfate Er Morphine Sulfate Brand 11 $154

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$30,764

Medicare's payments for the services billed

Medicare patients

190

Average age 71

Services billed

399

115 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 38%
Ischemic heart disease 36%
Diabetes 29%
Chronic kidney disease 29%
Heart failure 25%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record